Treatment effect of RAAS inhibitors on the two poor clinical grading scales of aSAH
| Outcomes | Exposures (n) | Poor outcomes, n (%) | Multivariable model* | |||
| Imputed data (n=1238) | Complete data (n=806) | |||||
| OR (95% CI) | P value | OR (95% CI) | P value | |||
| Hunt-Hess scale (1–3 vs 4–5) | Non-RAAS inhibitors (948) | 158 (16.7) | Reference | Reference | ||
| RAAS inhibitors (290) | 43 (14.8) | 0.653 (0.430 to 0.992) | 0.046 | 0.558 (0.340 to 0.918) | 0.022 | |
| WFNS scale (1–3 vs 4–5) | Non-RAAS inhibitors (948) | 298 (31.4) | Reference | Reference | ||
| RAAS inhibitors (290) | 84 (29.0) | 0.656 (0.469 to 0.918) | 0.014 | 0.587 (0.391 to 0.882) | 0.010 | |
*Multivariable model adjusted for age, sex, ethnicity, body mass index, smoking status, controlled status of hypertension, number of antihypertensive medications, ischaemic stroke, preadmission use of anti-platelet medication, preadmission use of anticoagulation medications, location of the reputed aneurysm, size of the aneurysm, shape irregularity of the aneurysm and number of intracranial aneurysms.
aSAH, aneurysmal subarachnoid haemorrhage; RAAS, renin-angiotensin-aldosterone system; WFNS, World Federation of Neurological Surgeons.